JP6223962B2 - トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット - Google Patents
トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット Download PDFInfo
- Publication number
- JP6223962B2 JP6223962B2 JP2014509868A JP2014509868A JP6223962B2 JP 6223962 B2 JP6223962 B2 JP 6223962B2 JP 2014509868 A JP2014509868 A JP 2014509868A JP 2014509868 A JP2014509868 A JP 2014509868A JP 6223962 B2 JP6223962 B2 JP 6223962B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- probe
- group
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11165267A EP2522369A1 (en) | 2011-05-09 | 2011-05-09 | Pretargeting kit, method and agents used therein |
| EP11165267.3 | 2011-05-09 | ||
| PCT/IB2012/052260 WO2012153254A1 (en) | 2011-05-09 | 2012-05-07 | Pretargeting kit for imaging or therapy comprising a trans - cyclooctene dienophile and a diene |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518861A JP2014518861A (ja) | 2014-08-07 |
| JP2014518861A5 JP2014518861A5 (enExample) | 2017-03-09 |
| JP6223962B2 true JP6223962B2 (ja) | 2017-11-01 |
Family
ID=44484790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509868A Active JP6223962B2 (ja) | 2011-05-09 | 2012-05-07 | トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9913921B2 (enExample) |
| EP (2) | EP2522369A1 (enExample) |
| JP (1) | JP6223962B2 (enExample) |
| CN (1) | CN103648533B (enExample) |
| AU (1) | AU2012252024B2 (enExample) |
| CA (1) | CA2835298C (enExample) |
| WO (1) | WO2012153254A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6215194B2 (ja) | 2011-05-16 | 2017-10-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 生体直交型薬物活性化 |
| EP2948186A4 (en) * | 2013-01-25 | 2016-10-05 | Sloan Kettering Inst Cancer | TETRAZINE / TRANSCYCLOOKTENE IN SOLID PHASE SYNTHESIS MARKED PEPTIDE |
| CN105611914B (zh) * | 2013-06-19 | 2020-09-08 | 加利福尼亚大学董事会 | 局部递送治疗剂的化学构造物 |
| US20160346409A1 (en) * | 2014-02-10 | 2016-12-01 | Mcmaster University | Targeted molecular imaging contrast agents |
| CN106659796B (zh) * | 2014-03-14 | 2021-04-30 | 加利福尼亚大学董事会 | Tco缀合物和治疗剂递送方法 |
| EP3125866B1 (en) * | 2014-04-04 | 2021-03-03 | President and Fellows of Harvard College | Refillable drug delivery devices and methods of use thereof |
| US10179775B2 (en) | 2014-08-11 | 2019-01-15 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
| WO2016164565A1 (en) * | 2015-04-08 | 2016-10-13 | University Of Delaware | Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling |
| WO2017031084A1 (en) | 2015-08-14 | 2017-02-23 | The Regents Of The University Of California | Poly(vinyl alcohol) nanocarriers |
| CN117567535A (zh) | 2015-09-10 | 2024-02-20 | 坦伯公司 | 生物正交组合物 |
| US11690825B2 (en) | 2016-03-09 | 2023-07-04 | Board Of Regents, The University Of Texas System | 20-HETE receptor (GPR75) antagonists and methods of use |
| WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| ES2983582T3 (es) | 2017-04-07 | 2024-10-23 | Tambo Inc | Composiciones bioortogonales |
| US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
| CN107746367B (zh) * | 2017-11-07 | 2020-05-26 | 清华大学 | β-石竹烯衍生物及其制备方法与应用 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| JP7554178B2 (ja) * | 2018-07-26 | 2024-09-19 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | イメージングのための組成物および方法 |
| EP3853234B1 (en) | 2018-09-18 | 2025-04-23 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| CN119823023A (zh) | 2018-10-10 | 2025-04-15 | 坦博公司 | 制备官能化环辛烯的工艺 |
| IL289095A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Activating components to cleave labels from biomolecules in vivo |
| CN110954514B (zh) * | 2019-12-02 | 2022-06-21 | 上海交通大学 | 适用于研究脂质体体内外分布的荧光示踪系统和方法 |
| WO2022038183A1 (en) | 2020-08-18 | 2022-02-24 | Rigshospitalet | Extracorporeal clearing traps based on inverse electron demand diels-alder cycloaddition for (pre)-targeted therapy and diagnostics |
| CA3239713A1 (en) * | 2021-12-08 | 2023-06-15 | Edward A. LEMKE | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
| KR20250141267A (ko) * | 2023-02-15 | 2025-09-26 | 태그웍스 파마슈티컬스 비.브이. | 개선된 특성을 가지는 테트라진 |
| CN118546131B (zh) * | 2024-05-10 | 2025-02-28 | 四川大学华西医院 | 四嗪聚集诱导发光探针前体、探针及其制备方法、应用 |
| CN119746111A (zh) * | 2024-12-04 | 2025-04-04 | 苏州大学 | 一种体内放射性标记降低肝脏辐射剂量的试剂及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3143578A (en) * | 1962-12-28 | 1964-08-04 | Union Carbide Corp | Preparation of tricyclo [8.2.1.02.9] trideca-5, 11-diene |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| US20030129191A1 (en) | 1992-12-23 | 2003-07-10 | Neorx Corporation | Pretargeting methods and compounds |
| ATE391713T1 (de) * | 2001-12-05 | 2008-04-15 | California Inst Of Techn | Enantioseletive umwandlung von alpha,beta- ungesättigten ketonen unter verwendung chiraler organischer katalysatoren |
| US8236949B2 (en) * | 2007-07-17 | 2012-08-07 | University Of Delaware | Tetrazine-based bio-orthogonal coupling reagents and methods |
| EP2361098B1 (en) | 2008-10-31 | 2019-08-28 | The General Hospital Corporation | Compositions and methods for delivering a substance to a biological target |
| DK2419142T3 (da) * | 2009-04-16 | 2020-02-10 | Tagworks Pharmaceuticals B V | Præmålretningskit, fremgangsmåde og deri anvendte midler |
| RU2011146362A (ru) * | 2009-04-16 | 2013-05-27 | Конинклейке Филипс Электроникс Н.В. | Набор для предварительного таргетинга, способ и средства, используемые в нем |
| EP2360167A1 (en) * | 2010-02-03 | 2011-08-24 | Deutsches Krebsforschungszentrum | Post-synthetic modification of nucleic acids by inverse Diels-Alder reaction |
| EP2595967B1 (en) * | 2010-07-23 | 2016-03-23 | University Of Delaware | Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes |
| JP6063384B2 (ja) * | 2010-10-14 | 2017-01-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | プレターゲットキット、プレターゲット方法及びその使用試薬 |
-
2011
- 2011-05-09 EP EP11165267A patent/EP2522369A1/en not_active Withdrawn
-
2012
- 2012-05-07 WO PCT/IB2012/052260 patent/WO2012153254A1/en not_active Ceased
- 2012-05-07 US US14/115,455 patent/US9913921B2/en active Active
- 2012-05-07 EP EP12724725.2A patent/EP2707035B1/en active Active
- 2012-05-07 CN CN201280034134.4A patent/CN103648533B/zh not_active Expired - Fee Related
- 2012-05-07 JP JP2014509868A patent/JP6223962B2/ja active Active
- 2012-05-07 CA CA2835298A patent/CA2835298C/en active Active
- 2012-05-07 AU AU2012252024A patent/AU2012252024B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140093450A1 (en) | 2014-04-03 |
| EP2707035B1 (en) | 2020-04-01 |
| US9913921B2 (en) | 2018-03-13 |
| EP2522369A1 (en) | 2012-11-14 |
| AU2012252024B2 (en) | 2017-06-29 |
| EP2707035A1 (en) | 2014-03-19 |
| JP2014518861A (ja) | 2014-08-07 |
| CA2835298C (en) | 2019-06-18 |
| WO2012153254A1 (en) | 2012-11-15 |
| CN103648533A (zh) | 2014-03-19 |
| CA2835298A1 (en) | 2012-11-15 |
| AU2012252024A1 (en) | 2014-01-09 |
| CN103648533B (zh) | 2017-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6223962B2 (ja) | トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット | |
| JP6368745B2 (ja) | プレターゲットキット、プレターゲット方法及びその使用試薬 | |
| CN102395380B (zh) | 预靶向试剂盒、方法和其中使用的试剂 | |
| JP5992435B2 (ja) | 循環からの生体分子の除去剤 | |
| CN102438656B (zh) | 预靶向试剂盒、方法和其中使用的试剂 | |
| JP2014506869A5 (enExample) | ||
| JP2014500307A5 (enExample) | ||
| JP2014515040A (ja) | 生体直交型薬物活性化 | |
| CA3143924A1 (en) | Agents for cleaving labels from biomolecules in vivo | |
| JP2024543046A (ja) | 大環状化合物及びその診断上の使用 | |
| CN103269721B (zh) | 预靶向试剂盒、方法和其中使用的试剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160607 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161109 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170131 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170310 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170420 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170713 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170804 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170905 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171004 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6223962 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |